Entresto 50 Mg 28 Tablets

Entresto 50 Mg 28 Tablets

Description:

Entresto 50 mg 28 tablets is a prescription cardiovascular medicine used in the long‑term management of chronic heart failure with reduced ejection fraction. It contains the fixed-dose combination sacubitril and valsartan, known as an angiotensin receptor neprilysin inhibitor (ARNI). Entresto helps reduce the risk of cardiovascular death and hospitalization for heart failure by improving heart function, lowering cardiac workload, and supporting better control of blood pressure in appropriate patients. This product is intended for adult use under strict medical supervision and is not a vitamin or food supplement.

Indications:

• Chronic heart failure (congestive heart failure, CHF) with reduced ejection fraction (HFrEF), New York Heart Association (NYHA) class II–IV.
• Reduction of the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction.
• Management of symptoms associated with heart failure such as shortness of breath, fatigue, reduced exercise tolerance, and fluid retention when used as part of standard heart failure therapy as directed by a cardiologist.

Active Ingredients / Key Components:

• Sacubitril – 24 mg per film‑coated tablet.
• Valsartan – 26 mg per film‑coated tablet.
• Total strength: Entresto 50 mg (24/26 mg) per tablet.
• Other inactive ingredients (excipients) are present to form the film‑coated tablet; full excipient list is not available in the provided information.

Dosage & Administration / How to Use:

• Use only as prescribed by a cardiologist or qualified healthcare professional.
• Typical recommended starting dose in adults: 49 mg/51 mg twice daily (this corresponds to one tablet of the 49/51 mg strength, not the 24/26 mg strength). The 24/26 mg (50 mg) tablets in this pack are usually used in patients requiring a lower starting dose (for example, those not previously on high‑dose ACE inhibitor/ARB, with renal impairment, or low blood pressure), according to physician judgment.
• Target maintenance dose: after 2–4 weeks, the dose is usually doubled to reach 97 mg/103 mg twice daily as tolerated, following medical guidance.
• Tablets are taken by mouth (oral use) twice daily, approximately 12 hours apart.
• Can be taken with or without food; take with a glass of water and swallow whole, do not crush or chew unless your doctor specifically advises otherwise.
• If switching from an ACE inhibitor, a washout period of at least 36 hours is required between stopping the ACE inhibitor and starting Entresto, to reduce the risk of angioedema.
• If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed tablet.
• Duration of therapy is long‑term and continuous, as advised by your doctor, with regular follow‑up for blood pressure, kidney function, and potassium levels.

Clinical Benefits:

• Helps reduce the risk of cardiovascular death and hospitalization due to heart failure in patients with chronic heart failure and reduced ejection fraction.
• Improves heart efficiency by combining neprilysin inhibition (sacubitril) with angiotensin II receptor blockade (valsartan), supporting better neurohormonal balance in heart failure.
• Supports better control of blood pressure, which helps decrease the workload on the weakened heart.
• May improve symptoms of heart failure such as breathlessness, fatigue, and exercise intolerance when used as part of guideline‑directed medical therapy.
• Clinically proven in large outcome trials to provide superior benefit compared with standard ACE inhibitor therapy in eligible patients with HFrEF.

Warnings & Contraindications:

• Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy, or hereditary/idiopathic angioedema.
• Contraindicated in pregnancy; medicines acting on the renin‑angiotensin system can cause injury and death to the developing fetus. Discontinue immediately if pregnancy is detected.
• Contraindicated in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
• Do not use concomitantly with ACE inhibitors; allow at least 36 hours between the last ACE inhibitor dose and the first dose of Entresto.
• Use with caution in patients with renal impairment, hyperkalemia, low blood pressure (hypotension), or volume depletion; regular monitoring of kidney function and serum potassium is required.
• May interact with other medicines such as potassium‑sparing diuretics, potassium supplements, NSAIDs, lithium, and other antihypertensives; inform your doctor about all medications and supplements you are taking.
• Consult your doctor before use if pregnant, planning pregnancy, or nursing. Breastfeeding is generally not recommended while taking this medicine unless specifically advised by a physician.
• Use with caution in patients with liver disease, kidney disease, dehydration, low sodium, or in elderly patients who may be more sensitive to blood pressure changes.
• May cause dizziness or light‑headedness; avoid driving or operating machinery until you know how the medicine affects you.
• Keep out of reach of children.

Side Effects:

• Common side effects may include low blood pressure (hypotension), dizziness, headache, fatigue, cough, and elevated potassium levels (hyperkalemia).
• Other possible side effects include kidney function changes, nausea, diarrhea, and mild swelling.
• Serious side effects: angioedema (swelling of the face, lips, tongue, or throat), severe dizziness, fainting, difficulty breathing, or sudden weight gain and swelling of legs/ankles. Seek immediate medical attention if any of these occur.
• Report any unusual or persistent symptoms to your doctor or pharmacist, especially signs of high potassium (muscle weakness, irregular heartbeat) or worsening heart failure (increasing shortness of breath, rapid weight gain).

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date printed on the pack. Store at or below the temperature recommended on the original packaging (specific temperature range is not available in the provided information).

Specifications:

• Form: Film‑coated tablet for oral use.
• Strength per tablet: sacubitril 24 mg + valsartan 26 mg (total 50 mg).
• Pack size: 28 tablets per pack.
• Intended use: Prescription cardiovascular medicine for adult patients with chronic heart failure with reduced ejection fraction.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.